Pharmaceutical policies and regulations of oral antiviral drugs for treatment of hepatitis C in Egypt—case study

References

• Bhamidimarri KR, Satapathy SK, Martin P. Hepatitis C virus and liver transplantation. Gastroenterol Hepatol (N Y). 2017;13(4):214–220.
   Google Scholar
• World Health Organization (WHO). Hepatitis C fact sheet. Updated 27 July 2020. https://www.who.int/news-room/fact-sheets/detail/hepatitis-c. Accessed 9 Apr 2021.
   Google Scholar
• Kandeel A, Genedy M, El-Refai S, Funk AL, Fontanet A, Talaat M. The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment. Liver Int. 2017;37(1):45–53.
   PubMed Web of Science ®Google Scholar
• Kouyoumjian SP, Chemaitelly H, Abu-Raddad LJ. Characterizing hepatitis C virus epidemiology in Egypt: systematic reviews, meta-analyses, and meta-regressions. Sci Rep. 2018;8(1):1661.
   PubMedGoogle Scholar
• Egypt’s Viral Hepatitis Program. Burden and response: an economic analysis 2017. The World Bank’s. http://documents.worldbank.org/curated/en/972381517328583384/pdf/123066-WP-PUBLIC-P157533-Burden-and-response-An-Economic-Analysis.pdf. Accessed 9 Apr 2021.
   Google Scholar
• Tsai SM, Kao JT, Tsai YF. How hepatitis C patients manage the treatment process of pegylated interferon and ribavirin therapy: a qualitative study. BMC Health Serv Res. 2016;16:247.
   Web of Science ®Google Scholar
• Sandmann L, Schulte B, Manns MP, Maasoumy B. Treatment of chronic hepatitis C: efficacy, side effects and complications. Visc Med. 2019;35(3):161–170.
   PubMed Web of Science ®Google Scholar
• Holmes JA, Rutledge SM, Chung RT. Direct-acting antiviral treatment for hepatitis C. Lancet. 2019;393(10179):1392–1394.
   Web of Science ®Google Scholar
• Bourlière M, Bronowicki JP, de Ledinghen V, Hézode C, Zoulim F, Mathurin P, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis. 2015;15(4):397–404.
   PubMed Web of Science ®Google Scholar
• Arab Republic of Egypt, Official Gazette. Law No. 151 of 2019 for establishing the Egyptian Drug Authority. https://manshurat.org/node/61255. Accessed 9 Apr 2021.
   Google Scholar
• Egyptian Drug Authority. Pharmacy Law 127 for 1955. [Online]. http://www.eda.mohp.gov.eg/Files/95_Pharmacy_law.pdf. Accessed 9 Apr 2021.
   Google Scholar
• State of information service. https://www.sis.gov.eg/section/0/4496?lang=en-us. Accessed 9 Apr 2021.
   Google Scholar
• Waheed Y, Siddiq M, Jamil Z, Najmi MH. Hepatitis elimination by 2030: progress and challenges. World J Gastroenterol. 2018;24(44):4959–4961.
   PubMed Web of Science ®Google Scholar
• Global Health Sector Strategy on Viral Hepatitis, 2016–2021. Geneva: World Health Organization; 2015. https://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/. Accessed 9 Apr 2021.
   Google Scholar
• Amin MEK, Nørgaard LS, Cavaco AM, Witry MJ, Hillman L, Cernasev A, et al. Establishing trustworthiness and authenticity in qualitative pharmacy research. Res Soc Adm Pharm. 2020;16(10):1472–1482.
   PubMed Web of Science ®Google Scholar
• Palinkas LA, Horwitz SM, Green CA, Wisdom JP, Duan N, Hoagwood K. Purposeful sampling for qualitative data collection and analysis in mixed method implementation research. Adm Policy Ment Health. 2015;42(5):533–544.
   PubMed Web of Science ®Google Scholar
• Cresswell JW, Plano Clark VL. Designing and conducting mixed method research. 2nd ed. Thousand Oaks: Sage; 2011.
   Google Scholar
• Wanis H. Chapter 4—pharmaceutical pricing in Egypt. In: Zaheer-Ud-Din B, Editor. Pharmaceutical prices in the 21st century. Cham: Springer; 2015. https://doi.org/10.1007/978-3-.319-.12169-7.
   Google Scholar
• Egyptian Pricing Decree no499/2012. Egyptian Drug Authority. In Arabic at http://www.eda.mohp.gov.eg/Files/474_499.pdf. Accessed 9 Apr 2021.
   Google Scholar
• Lashen SA, Shamseya MM, Madkour MA, Aboufarrag GA. Tolerability and effectiveness of generic direct-acting antiviral drugs in eradication of hepatitis C genotype 4 among Egyptian patients. Liver Int. 2019;39(5):835–843.
   PubMed Web of Science ®Google Scholar
• Abozeid M, Alsebaey A, Abdelsameea E, Othman W, Elhelbawy M, Rgab A, et al. High efficacy of generic and brand direct acting antivirals in treatment of chronic hepatitis C. Int J Infect Dis. 2018;75:109–114.
   PubMed Web of Science ®Google Scholar
• Ndomondo-Sigonda M, Miot J, Naidoo S, Dodoo A, Kaale E. Medicines regulation in Africa: current state and opportunities. Pharm Med. 2017;31(6):383–397.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration (FDA). Learn about FDA, its mission, history, how it’s organized, and more. https://www.fda.gov/. Accessed 9 Apr 2021.
   Google Scholar
• European Medicines Agency. The European Medicines Agency’s contribution to science, medicines and health in 2019. https://www.ema.europa.eu/en/documents/annual-report/2019-annual-report-european-medicines-agency_en.pdf. Accessed 9 Apr 2021.
   Google Scholar
• Egyptian Drug Authority. Ministry Decree 425/2015. [Online]. http://www.eda.mohp.gov.eg/Files/766_425_2015.pdf. Accessed 9 Apr 2021.
   Google Scholar
• Li G, De Clercq E. Current therapy for chronic hepatitis C: the role of direct-acting antivirals. Antivir Res. 2017;142:83–122.
   Web of Science ®Google Scholar
• Burstow NJ, Mohamed Z, Gomaa AI, Sonderup MW, Cook NA, Waked I, et al. Hepatitis C treatment: where are we now? Int J Gen Med. 2017;10:39–52.
   PubMed Web of Science ®Google Scholar
• Gritsenko D, Hughes G. Ledipasvir/sofosbuvir (Harvoni): improving options for hepatitis C virus infection. Pharm Ther. 2015;40(4):256–276.
   Google Scholar
• Keating GM, Vaidya A. Sofosbuvir: first global approval. Drugs. 2014;74(2):273–282.
   PubMed Web of Science ®Google Scholar
• Montgomery M, Ho N, Chung E, Marzella N. Daclatasvir (Daklinza): a treatment option for chronic hepatitis C infection. P T. 2016;41(12):751–755.
   Google Scholar
• Raedler LA. Once-a-day Harvoni (ledipasvir plus sofosbuvir), a new oral combination for the treatment of patients with genotype 1 chronic hepatitis C infection. Am Health Drug Benefits. 2015;8(Spec Feature):54–58.
   PubMedGoogle Scholar
• Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483–1493.
   PubMed Web of Science ®Google Scholar
• Zhang S, Bastian ND, Griffin PM. Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US. BMC Gastroenterol. 2015;15:98.
   PubMed Web of Science ®Google Scholar
• Egyptian Initiative for Personal Rights. HCV treatment in Egypt: why cost remains a challenge? November 2014. https://www.eipr.org/sites/default/files/pressreleases/pdf/hcv_treatment_in_egypt.pdf. Accessed 9 Apr 2021.
   Google Scholar
• Hill A, Simmons B, Gotham D, Fortunak J. Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C. J Virus Erad. 2016;2(1):28–31.
   Google Scholar
• Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, de Joncheere K, et al. Prices, costs, and affordability of new medicines for hepatitis C in 30 countries: an economic analysis. PLoS Med. 2016;13(5):e1002032.
   PubMed Web of Science ®Google Scholar
• World Bank. World Bank list of economies (June 2020). https://datahelpdesk.worldbank.org/knowledgebase/articles/906519. Accessed 9 Apr 2021.
   Google Scholar
• Arab Republic of Egypt, Egyptian Drug Authority. http://196.46.22.218/EDASearch/SearchRegDrugs.aspx. Accessed 9 Apr 2021.
   Google Scholar
• Hashemite Kingdom of Jordan. Jordan Food and Drug Administration. http://jfda.jo/Pages/viewpage.aspx?pageID=184. Accessed 9 Apr 2021.
   Google Scholar
• Republic of Lebanon, Ministry of Public Health. https://moph.gov.lb/en/Pages/3/3101/drugs-public-price-list-. Accessed 9 Apr 2021.
   Google Scholar
• Kingdom of Morocco, Ministry of Health. https://www.sante.gov.ma/sites/Ar/medicaments/Pages/PMed.aspx. Accessed 9 Apr 2021.
   Google Scholar
• Kingdom of Saudi Arabia, Saudi Food and Drug Authority. https://www.sfda.gov.sa/en/drug/search/Pages/default.aspx. Accessed 9 Apr 2021.
   Google Scholar
• United Arab Emirates, Ministry of Health and Prevention. https://www.mohap.gov.ae/en/services/request-for-a-price-list-of-registered-medications. Accessed 9 Apr 2021.
   Google Scholar
• Abdellatif L, Zaky M. Characteristics of private markets and accessibility of small and medium enterprises to public procurement markets: pharmaceuticals in Egypt. J Public Procure. 2015;15(4):476–513.
   Google Scholar
• Gericke CA, Britain K, Elmahdawy M, Elsisi G. Health system in Egypt. In: van Ginneken E, Busse R, Editors. Health care systems and policies. Health services research. New York: Springer; 2018.
   Google Scholar
• Arab Republic of Egypt. 2002. Law 82/2002 on the protection of intellectual property rights. Official Gazette (22), 2 June 2002. http://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_trips_e.htm. Accessed 9 Apr 2021.
   Google Scholar
• World Intellectual Property Organization. Agreement between the Egyptian Academy of Scientific Research and Technology and the International Bureau of the World Intellectual Property Organization in relation to the functioning of the Egyptian Patent Office as an International Searching Authority and International Preliminary Examining Authority under the Patent Cooperation Treaty. https://www.wipo.int/export/sites/www/pct/en/texts/agreements/ag_eg.pdf. Accessed 9 Apr 2021.
   Google Scholar
• Boldrin M, Levine DK. The case against patents. J Econ Perspect. 2013;27:3–22.
   Web of Science ®Google Scholar
• 't Hoen E, Passarelli CA. The role of intellectual property rights in treatment access: challenges and solutions. Curr Opin HIV AIDS. 2013;8(1):70–4.
   Web of Science ®Google Scholar
• Egypt Pharmaceuticals & Healthcare Report, 2019. https://nations-emergentes.org/wp-content/uploads/2019/02/egypt-pharmaceutical-survey.pdf. Accessed 9 Apr 2021.
   Google Scholar
• Egyptian Drug Authority. Ministry Decree 539/2007. [Online]. http://www.eda.mohp.gov.eg/Files/105_Minister_Decree_539_Both.pdf. Accessed 9 Apr 2021.
   Google Scholar
• Broojerdi AK, Sillo HB, Dehaghi RO, Ward M, Refaat M, Parry J. The World Health Organization global benchmarking tool an instrument to strengthen medical products regulation and promote universal health coverage. Front Med. 2020;19(7):457.
   Google Scholar